GRI Bio Inc
GRI
NASDAQ
Biotechnology
$1.67
USD
-0.10 (-5.65%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.13M
Volume 105.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-10.91M
TTM
-16.5%
YoY
Operating Cash Flow
$-12.13M
TTM
-49.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.4 | 1.0 | 1.6 | 1.0 | 1.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.1 | 2.9 | 3.4 | 2.7 | 2.0 |
Operating Income | -3.1 | -2.9 | -3.4 | -2.7 | -2.0 |
EBITDA | -3.1 | -2.9 | -3.4 | -2.7 | -2.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -3.0 | -2.9 | -3.4 | -2.7 | -2.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.0 | -2.9 | -3.4 | -2.7 | -2.0 |
Consolidated Net Income / Loss | -3.0 | -2.9 | -3.4 | -2.7 | -2.0 |
Net Income Attributable to Common Shareholders | -3.0 | -2.9 | -3.4 | -2.7 | -2.0 |
Basic EPS | -$162.30 | -$1.31 | -$1.28 | $0.00 | -$1.61 |
Diluted EPS | -$162.30 | -$1.31 | -$1.28 | $0.00 | -$1.61 |
Basic Shares Outstanding | 0.0M | 2.2M | 2.6M | 0.0M | 1.2M |
Diluted Shares Outstanding | 0.0M | 2.2M | 2.6M | 0.0M | 1.2M |